CCL-229 LoVo 人結腸癌細胞
ATCC® Number: CCL-229?
Designations: LoVo
Depositors: M Romsdahl
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: colon
Tumor Stage: Dukes' type C, grade IV
Disease: colorectal adenocarcinoma
Derived from metastatic site: left supraclavicular region
Cellular Products: carcinoembryonic antigen (CEA) 908 ng/10 exp6 cells/10 days
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications: transfection host (Roche FuGENE® Transfection Reagents)
Tumorigenic: Yes
Reverse Transcript: negative
Oncogene: myc +; myb + ; ras +; fos +; p53 +; sis -; abl -; ros -; src -
Antigen Expression: HLA A11, B15, B17, Cw1, Cw3; blood type B
DNA Profile (STR): Amelogenin: XY
CSF1PO: 10,11,13,14
D13S317: 8, 11
D16S539: 9, 12
D5S818: 11, 12, 13
D7S820: 9.3,10, 11
TH01: 9.3
TPOX: 8,9
vWA: 17,18
Cytogenetic Analysis: The stemline chromosome number is hyperdiploid with the 2S component occurring at about 2.7% and 3 marker chromosomes were common to all S metaphases. Karyotypes were generally homogeneous and stable.
Isoenzymes: ES-D, 1
G6PD, B
PGD, A
PGM1, 2
PGM3, 1-2
Age: 56 years
Gender: male
Comments: LoVo was initiated in 1971 from a fragment of a metastatic tumor nodule in the left supraclavicular region of a 56-year-old Caucasian male patient with a histologically proven diagnosis of adenocarcinoma of the colon. [1049]
The cells are negative for expression of CSAp (CSAp-) and colon antigen 3.
The line is positive for expression of c-myc, K-ras, H-ras, N-ras, Myb, sis and fos oncogenes. [22861]
Myb, and fos oncogenes. [22861]
N-myc and sis oncogene expression were not detected. [22861]
Tumor specific nuclear matrix proteins CC-3 and CC-4 are expressed. [23341]
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2004
recommended serum:ATCC 30-2020
References: 1047: Drewinko B, et al. Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line. J. Natl. Cancer Inst. 61: 75-83, 1978. PubMed: 276641
1048: Drewinko B, Yand LY. Restriction of CEA synthesis to the stationary phase of growth of cultured human colon carcinoma cells. Exp. Cell Res. 101: 414-416, 1976. PubMed: 964319
1049: Drewinko B, et al. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 36: 467-475, 1976. PubMed: 1260746
22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874
23341: Keesee SK, et al. Nuclear matrix proteins in human colon cancer. Proc. Natl. Acad. Sci. USA 91: 1913-1916, 1994. PubMed: 8127905
26057: Drewinko B, et al. Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives. Cancer Res. 39: 2630-2636, 1979. PubMed: 445465
32913: Miranda L, et al. Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 93: 7695-7700, 1996. PubMed: 8755538
